We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Macrogenics Inc
10 own
15 watching
Current Price
$3.19
$0.15
(4.93%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
396.5M
52-Week High
21.88000
52-Week Low
2.95100
Average Volume
0.63M
Dividend Yield
--
P/E Ratio
--
Market Capitalization396.5M52-Week High21.8800052-Week Low2.95100Average Volume0.63MDividend Yield--P/E Ratio--What does the Macrogenics Inc do?
MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate. In addition, the company's products include MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; and MGD014, a DART molecule that targets human immunodeficiency virus, or HIV-infected cells, and CD3-expressing T cells. It has collaboration and license agreements with Janssen Biotech, Inc.; Les Laboratoires Servier and Institut de Recherches Servier; Boehringer Ingelheim GmbH; Pfizer, Inc.; and Green Cross Corp. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Read More
How much money does Macrogenics Inc make?
News & Events about Macrogenics Inc.
Zolmax
1 year ago
MacroGenics, Inc. (NASDAQ:MGNX Get Rating) has been assigned a consensus rating of Moderate Buy from the thirteen analysts that are currently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and five have assigned a buy ...
Globe Newswire
1 year ago
ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administrations (FDA) ...
Zolmax
1 year ago
MacroGenics, Inc. (NASDAQ:MGNX Get Rating) major shareholder Target N. V. Biotech acquired 500,000 shares of the businesss stock in a transaction dated Tuesday, February 14th. The stock was acquired at an average price of $5.07 per share, for a total transaction of $2,535,000.00. Following the ...
Zolmax
1 year ago
MacroGenics, Inc. (NASDAQ:MGNX Get Rating) major shareholder Target N. V. Biotech acquired 500,000 shares of the businesss stock in a transaction dated Tuesday, February 14th. The stock was acquired at an average price of $5.07 per share, for a total transaction of $2,535,000.00. Following the ...
Ticker Report
1 year ago
MacroGenics, Inc. (NASDAQ:MGNX Get Rating) major shareholder Target N. V. Biotech acquired 500,000 shares of the businesss stock in a transaction dated Tuesday, February 14th. The stock was acquired at an average price of $5.07 per share, for a total transaction of $2,535,000.00. ...
Frequently Asked Questions
Frequently Asked Questions
What is Macrogenics Inc share price today?
Can Indians buy Macrogenics Inc shares?
How can I buy Macrogenics Inc shares from India?
Can Fractional shares of Macrogenics Inc be purchased?
What are the documents required to start investing in Macrogenics Inc stocks?
What is today’s traded volume of Macrogenics Inc?
What is today’s market capitalisation of Macrogenics Inc?
What is the 52-Week High and Low Range of Macrogenics Inc?
What percentage is Macrogenics Inc down from its 52-Week High?
What percentage is Macrogenics Inc up from its 52-Week Low?
Current Price
$3.19
$0.15
(4.93%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.